Literature DB >> 24764199

Can valproic acid be an inducer of clozapine metabolism?

F J Diaz1, C B Eap2, N Ansermot2, S Crettol2, E Spina3, J de Leon4.   

Abstract

INTRODUCTION: Prior clozapine studies indicated no effects, mild inhibition or induction of valproic acid (VPA) on clozapine metabolism. The hypotheses that (i) VPA is a net inducer of clozapine metabolism, and (ii) smoking modifies this inductive effect were tested in a therapeutic drug monitoring study.
METHODS: After excluding strong inhibitors and inducers, 353 steady-state total clozapine (clozapine plus norclozapine) concentrations provided by 151 patients were analyzed using a random intercept linear model.
RESULTS: VPA appeared to be an inducer of clozapine metabolism since total plasma clozapine concentrations in subjects taking VPA were significantly lower (27% lower; 95% confidence interval, 14-39%) after controlling for confounding variables including smoking (35% lower, 28-56%). DISCUSSION: Prospective studies are needed to definitively establish that VPA may (i) be an inducer of clozapine metabolism when induction prevails over competitive inhibition, and (ii) be an inducer even in smokers who are under the influence of smoking inductive effects on clozapine metabolism. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24764199      PMCID: PMC4229130          DOI: 10.1055/s-0034-1371866

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  50 in total

1.  Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied.

Authors:  Jose de Leon; Francisco J Diaz; Edoardo Spina
Journal:  J Clin Psychiatry       Date:  2010-07       Impact factor: 4.384

2.  Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  J Clin Psychopharmacol       Date:  2009-06       Impact factor: 3.153

Review 3.  A mechanistic approach to antiepileptic drug interactions.

Authors:  G D Anderson
Journal:  Ann Pharmacother       Date:  1998-05       Impact factor: 3.154

4.  Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism.

Authors:  C Sachse; S Ruschen; M Dettling; J Schley; S Bauer; B Müller-Oerlinghausen; I Roots; J Brockmöller
Journal:  Clin Pharmacol Ther       Date:  1999-10       Impact factor: 6.875

Review 5.  The dosing of atypical antipsychotics.

Authors:  Jose de Leon; Scott C Armstrong; Kelly L Cozza
Journal:  Psychosomatics       Date:  2005 May-Jun       Impact factor: 2.386

6.  Valproic Acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking.

Authors:  Tore Haslemo; Kristine Olsen; Hilde Lunde; Espen Molden
Journal:  Ther Drug Monit       Date:  2012-10       Impact factor: 3.681

7.  A case of pharmacokinetic interference in comedication of clozapine and valproic acid.

Authors:  A Conca; W Beraus; P König; R Waschgler
Journal:  Pharmacopsychiatry       Date:  2000-11       Impact factor: 5.788

8.  Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report.

Authors:  Jose de Leon; Francisco J Diaz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-09       Impact factor: 5.067

9.  Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.

Authors:  Edoardo Spina; Concetta D'Arrigo; Vincenza Santoro; Maria Rosaria Muscatello; Gianluca Pandolfo; Rocco Zoccali; Francisco J Diaz; Jose de Leon
Journal:  Ther Drug Monit       Date:  2009-12       Impact factor: 3.681

Review 10.  Pharmacokinetics, drug interactions, and tolerability of valproate.

Authors:  C Lindsay DeVane
Journal:  Psychopharmacol Bull       Date:  2003
View more
  8 in total

1.  Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models.

Authors:  Francisco J Diaz
Journal:  Stat Med       Date:  2016-06-20       Impact factor: 2.373

2.  The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.

Authors:  Yan-Nan Zang; Fang Dong; An-Ning Li; Chuan-Yue Wang; Gui-Xin Guo; Qian Wang; Yan-Fang Zhang; Lei Zhang; Jose de Leon; Can-Jun Ruan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03-06       Impact factor: 2.441

3.  Reliable clinical serum analysis with reusable electrochemical sensor: Toward point-of-care measurement of the antipsychotic medication clozapine.

Authors:  Mijeong Kang; Eunkyoung Kim; Thomas E Winkler; George Banis; Yi Liu; Christopher A Kitchen; Deanna L Kelly; Reza Ghodssi; Gregory F Payne
Journal:  Biosens Bioelectron       Date:  2017-04-12       Impact factor: 10.618

4.  Three patients needing high doses of valproic Acid to get therapeutic concentrations.

Authors:  James Jackson; Betsy McCollum; Judy Ognibene; Francisco J Diaz; Jose de Leon
Journal:  Case Rep Psychiatry       Date:  2015-04-27

5.  Considerations of HLA, Renal Failure, Valproic Acid Use, and Current Treatment Guidelines in Clozapine-Induced Agranulocytosis.

Authors:  Melissa Sussman; Michael Epifania; Derrick Eng; Jae Cho; Richard Steward
Journal:  Case Rep Psychiatry       Date:  2021-02-20

6.  The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial.

Authors:  Francisco J Diaz; Richard C Josiassen; Jose de Leon
Journal:  J Clin Psychopharmacol       Date:  2018-10       Impact factor: 3.153

7.  Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users.

Authors:  Xuan Zhang; Jose de Leon; Benedicto Crespo-Facorro; Francisco J Diaz
Journal:  J Biopharm Stat       Date:  2020-06-08       Impact factor: 1.503

Review 8.  The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism.

Authors:  Hueng-Chuen Fan; Herng-Shen Lee; Kai-Ping Chang; Yi-Yen Lee; Hsin-Chuan Lai; Pi-Lien Hung; Hsiu-Fen Lee; Ching-Shiang Chi
Journal:  Int J Mol Sci       Date:  2016-08-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.